Mankind Pharma was incorporated on July 3, 1991. The company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.
| Bidding Dates |
|---|
| 25 Apr 2023 - 27 Apr 2023 |
| Subscription |
|---|
| 15.32x Oversubscribed |
| Minimum Investment | Minimum Lot | Maximum Lot | Lot Size | Number of Shares | Issue Price Band | Post Issue Promoter Holding % | Issue Size | IPO Document |
|---|---|---|---|---|---|---|---|---|
| ₹14,040 | 1 | 14 | 13 | 40.1 M | ₹1026 - ₹1080 | 90 % | ₹41100.4 M - ₹43263.5 M | RHP DOC |
Mankind Pharma IPO SUBSCRIPTION STATUS
27 Apr '23Mankind Pharma IPO overall subscription rate was 15.32 times the total available shares
Mankind Pharma IPO retail subscription rate was 0.92 times in the retail segment
Mankind Pharma IPO non-institutional investor subscription rate was 3.8 times in the non-institutional investor category
Mankind Pharma IPO Qualified Institutional Bidder subscription rate was 49.16 times the available shares for Qualified Institutional Bidder
| Day | Retail Individual Investor | HNI (NII) Investors | Qualified Institutional Buyers |
|---|---|---|---|
| Category Reservation | 35% | 15% | 50% |
27 Apr 2023 (Day 3) | 0.92x | 3.8x | 49.16x |
26 Apr 2023 (Day 2) | 0.25x | 1.02x | 1.86x |
25 Apr 2023 (Day 1) | 0.1x | 0.33x | 0.08x |
Mankind Pharma FINANCIALS
| Period | Net Profit (Rs in millions) | Revenue from Operations (Rs in millions) | Cash Flow from Operations (Rs in millions) | Free Cash Flow (Rs in millions) | Margins |
| 9MFY23 | 10,159.8 | 66,967.7 | 13,289.0 | 6,759.8 | 22.3% |
| 9MFY22 | 12,602.4 | 60,557.9 | 11,585.5 | 7,877.8 | 28.3% |
| FY22 | 14,529.6 | 77,815.6 | 9,197.8 | -14,226.0 | 25.8% |
| FY21 | 12,930.3 | 62,144.3 | 11,372.4 | 8,256.7 | 26.7% |
| FY20 | 10,561.5 | 58,652.3 | 10,697.1 | 8,529.8 | 24.7% |
Mankind Pharma IPO SUBSCRIPTION STATUS DETAILS
Mankind Pharma had 40.1 M shares on offer
Mankind Pharma IPO offer price was in the range ₹1026 - ₹1080
Mankind Pharma IPO minimum Investment was ₹14040
Mankind Pharma IPO issue size was ₹ 41100.4 M - ₹ 43263.5 M
Mankind Pharma had a minimum lot size of 13 Shares per application
Mankind Pharma NUMBER OF SHARES ON OFFER
Mankind Pharma IPO IMPORTANT DATES
| Issue Open Date | 25 Apr 2023 |
| Issue close Date | 27 Apr 2023 |
| Allotment Date | 03 May 2023 |
| Refund Date | 04 May 2023 |
| Demat Account Credit Date | 05 May 2023 |
| Listing Date | 09 May 2023 |
| Listing on Exchange(s) | NSE and BSE |
| Mankind Pharma Allotment Status | Exchange |
Mankind Pharma IPO subscription opened on 25 Apr 2023, and closed on 27 Apr 2023
IPO allotment for Mankind Pharma was finalized on Wednesday, 03 May 2023
IPO listing for Mankind Pharma was on NSE and BSE on Tuesday, 09 May 2023
Mankind Pharma IPO LISTING GAINS
| Issue Price (adjusted) | 1080.0 |
| Listing Open Price | 1300.0 |
| Listing Close Price | 1422.3 |
| Listing Gain% | 20.4% |
| Current Gain% | 127.4% |
Mankind Pharma Peer
| Stock | Stock Price | Market Cap (Rs crore) | PE TTM | PEG TTM | PS TTM | ROE% | ROA% | Annual Revenue (Rs crore) | Annual Revenue Growth % | Annual Net Profit (Rs crore) | Annual Net Profit Growth % | EPS TTM | EPS TTM Growth % |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Mankind Pharma Ltd. | 2456 | 98384.5 | 49.7 | 6.3 | 6.9 | 11.7 | 6.8 | 14636.4 | 14.8 | 1912.9 | -3.9 | 49.5 | 7.9 |
| Sun Pharmaceutical Industries Ltd. | 1945 | 466670.7 | 38.6 | 2.3 | 7.8 | 13.7 | 10.6 | 60433.8 | 10.8 | 11479.4 | 5 | 50.4 | 16.6 |
| Divi's Laboratories Ltd. | 8275 | 219675.3 | 75.1 | 2.8 | 19.6 | 15.3 | 12.8 | 11067 | 14 | 2568 | 17.2 | 110.2 | 26.8 |
| Torrent Pharmaceuticals Ltd. | 4924 | 187293.2 | 85.9 | 9.6 | 11.9 | 25.8 | 4.9 | 13886.2 | 20.3 | 2163.4 | 13.2 | 57.3 | 8.9 |
| Cipla Ltd. | 1463.8 | 118253.6 | 35.1 | -0.9 | 4.2 | 11.3 | 9.1 | 29044.6 | 2.2 | 3879.2 | -26.4 | 41.7 | -37.5 |
| Zydus Lifesciences Ltd. | 1114.2 | 112114.6 | 22.2 | 2.3 | 4.1 | 18.6 | 9.6 | 27657.9 | 17.6 | 5040 | 11.4 | 50.1 | 9.6 |
Mankind Pharma IPO Reports
Mankind Pharma INFORMATION ON IPO ISSUE
About Mankind Pharma
Mankind Pharma was incorporated on July 3, 1991. The company is engaged in developing, manufacturing and marketing a diverse range of pharmaceutical formulations across various acute and chronic therapeutic areas, as well as several consumer healthcare products.
Object of the Issue
- To carry out the offer for sale of 4,00,58,844 equity shares aggregating to Rs 4326.36 crore
- To achieve the benefits of listing equity shares on the stock exchanges
Mankind Pharma - PROMOTERS
| Name |
|---|
| Ramesh Juneja |
| Rajeev Juneja |
| Sheetal Arora |
| Ramesh Juneja FamilyTrust |
| Rajeev Juneja Family Trust |
| Prem Sheetal Family Trust |
Mankind Pharma Book Running Lead Manager
Kotak Mahindra Capital Company Limited
mankindpharma.ipo@kotak.com
Axis Capital Limited
mankindpharma.ipo@axiscap.in
Mankind Pharma Book Running Lead Managers
IIFL Securities Limited
mankind.ipo@iiflcap.com
Jefferies India Private Limited
Mankindpharma.ipo@jefferies.com
J.P. Morgan India Private Limited
mankind_IPO@jpmorgan.com
Mankind Pharma Registrar to the Offer
KFinTechnologies Private Limited
mankind.ipo@kfintech.com
Mankind Pharma Strengths
Domestic-focused business
The company is among the largest domestic formulations businesses in India with domestic sales of approximately Rs 8,219.8 crore during FY22, ranking fourth in IPM in terms of domestic sales.
Growing faster than IPM
Between FY20-22, the company's domestic sales have grown at a CAGR of approximately 16%, outperforming the overall IPM growth in domestic sales of approximately 11% by approximately 1.5 times
Diversified portfolio
The company has a diversified portfolio of products across leading therapeutic areas
Wide market and distribution coverage
The company has a wide marketing and distribution presence and has one of the largest distribution networks in the IPM with 11,196 medical representatives and 3,195 field managers as of March 31, 2022. During FY22, over 80% of doctors in India prescribed the company's formulations.
Mankind Pharma Risks
Dependent on smaller market
The company derives a significant portion of its revenue from operations from a limited number of markets
Outstanding legal proceedings
There are outstanding legal proceedings involving the company, its promoters, its subsidiaries and its directors
Dependent on tax incentive schemes
The company is currently entitled to certain tax incentives and export promotion schemes. Any decrease in or discontinuation of policies relating to tax, duties or other such levies applicable to the company may affect the results of operations
IPO FAQs
This IPO consists of an offer for sale of up to Rs 4,326.4 crore, of 40,058,844 shares.
The promoters of the company are Ramesh Juneja, Rajeev Juneja, Sheetal Arora, Ramesh Juneja FamilyTrust, Rajeev Juneja Family Trust and Prem Sheetal Family Trust.
The category allocation of qualified institutional buyers is 50.0%, the category allocation of non individual investors or high networth individuals is 15.0% and for retail investors it is 35.0%.
The price band of the IPO is Rs 1026.0 - 1080.0.
The IPO application opens on Apr 25, 2023 and closes on Apr 27, 2023.
The minimum lot size for the IPO is 13. The maximum lot size for the IPO is 182.
For all category investors, the minimum application amount for this IPO is Rs. 14,040.0, the maximum value for this IPO is Rs 196,560.0.
This IPO will be allotted on May 03, 2023.
The refund will be credited to your account on May 04, 2023.
The allotted shares will be credited to your demat on May 05, 2023.
Mankind Pharma Ltd.’s shares listed on the stock exchanges on May 09, 2023.